博奥信生物(南京)有限公司
江苏省南京市江北新区龙山南路3-1号中丹园二期D座5层,210061
电话:+86-25-86507191
邮箱:sales@biosion.com

公司简介

 

专注创新抗体药物开发

领导团队

陈明久 博士

创始人,董事长兼首席执行官

在创立博奥信之前,陈明久博士曾任美国战略诊断公司(SDIX)资深运营总监,负责该公司单克隆抗体开发外包服务的日常运营管理工作。在此之前,陈博士曾任美国雅培公司(现艾伯维AbbVie)资深科学家,参与多项创新抗体药物开发,其中包括ABT165(处于临床二期)。陈博士拥有20多年生物药医抗体开发经验,擅长抗体药物开发过程中竞争性创新发现及临床前开发。陈博士于美国德克萨斯大学圣安东尼奥医学中心获得分子医学博士。

 

 

 

 

 

Hugh Davis博士

首席运营官、博奥信美国分公司总裁

Davis博士拥有30多年制药行业经验。加盟博奥信前,Davis博士在方达医药(Frontage LaboratoriesInc.)任首席商务官,带领方达医药于20195月成功在香港上市。2018年加入方达医药之前,Davis博士于2001年加入强生公司,担任生物药科学部副总裁。在强生任职期间,Davis博士领导的团队对多项生物药(包括Remicade®Stelara® Simponi®Sylvant®Darzalex®Tremfya®的开发及上市做出重要贡献。在此之前,Davis博士于供职于葛兰素史克(Glaxo SmithKline),为该公司临床药理学部药理动力学实验室负责人。Davis博士拥有美国维拉诺瓦大学(Villanova University)生物化学博士学位,并在森托科杨森制药公司)完成了博士后研究。

 

 

 

马志清 博士

副总裁,创新抗体技术平台负责人

马志清博士拥有30多年肿瘤生物学、转基因疾病模型的创建以及生物大分子和小分子药物临床前的开发经验。马博士曾任FZata生物技术公司研发总监,负责治疗性纳米抗体的研发。也曾在马里兰大学任教和担任辞典制药(Lexicon Pharmaceutical)资深科学家。马博士从中国药科大学获得药学学士和神经药理学硕士,从意大利米兰大学获得生物技术博士,并在美国贝勒医学院完成博士后研究。

 

 

 

 

Mike Liu, Ph. D., MBA

Dr. Liu has multiple years of experience in licensing & business development, market development, and biomedical research. He was on the Executive Committee of Sino-American Pharmaceutical Professionals Association (SAPA) from 2004 to 2010. From 2016 to June 2020, Dr. Liu was Senior Vice President of Global Corporate Development at Alphamab, a leading innovative biotech company in China. He was primarily responsible for global business development initiatives and closed multiple deals licensing, research collaboration and strategic partnership. From 2011 to May 2016, Dr. Liu was Head of Global Business Development at Hengrui Pharmaceuticals. At Hengrui, he closed dozens of licensing and partnership agreements with leading multi-national and Chinese companies, such as the $795-million out-licensing deal with Incyte for PD-1 mAb and in-licensing of Rolapitant from Tesaro. Prior to Hengrui, Dr. Liu held increasing responsibilities for global commercial development at Alexion Pharmaceuticals and licensing & business development at Purdue Pharma L.P., a leading private pharmaceutical company in the U.S. He closed multiple deals in commercialization partnering, product acquisition, licensing, and research alliance. Dr. Liu obtained his bachelor degree in biochemistry at Nanjing University, Ph.D. degree in cancer biology at Eppley Cancer Institute in the US, and MBA degree at Washington University in St. Louis. In his earlier academic career, Dr. Liu conducted translational medical research at Yale University School of Medicine.